Datameds AI, Inc. income statement

In fiscal 2025, Datameds AI, Inc. reported revenue of $23.3m, up 28.7% on the year before, operating income of −$93.7m (a -401.7% margin) and net income of −$101m, or −$1.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Datameds AI, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	18	23	8
Cost of revenue	16	30	15
Gross profit	2	−6	−7
Selling and marketing	—	1	2
General and administrative	7	70	46
Operating income	−6	−94	−70
Interest expense	1	5	6
Income before tax	−7	−101	−88
Net income	−7	−101	−88
Diluted EPS	−$0.15	−$1.43	—
Diluted shares (average)	47m	71m	—
EBITDA	−5	−91	−68

US$ millions unless shown otherwise. Fiscal quarters.

Datameds AI, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	6	12	11	8	3	2	2	2
Cost of revenue	5	11	10	7	3	10	1	2
Gross profit	1	1	1	1	0	−8	0	0
Selling and marketing	—	—	0	0	1	0	1	0
General and administrative	2	4	31	5	30	4	5	7
Operating income	−2	−4	−31	−6	−32	−25	−6	−7
Interest expense	0	1	1	1	1	1	2	2
Income before tax	−2	−4	−32	−7	−34	−28	−8	−18
Net income	−2	−4	−32	−7	−34	−28	−8	−18
Diluted EPS	−$2.00	−$0.10	−$0.62	−$5.40	−$23.00	−$0.25	−$3.50	−$7.13
EBITDA	−1	−3	−31	−5	−31	−25	−6	−7

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MEDS vs MNDR DRIO vs MEDS MEDS vs WORX

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Datameds AI, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Datameds AI, Inc.